Table 2.
Antiproliferative activities of GA, its heterocyclic derivatives, and cisplatin against several cancer cell lines and the nontumoral BJ cell line.
| Compound | Cell line (IC50, µM) 1 | |||||||
|---|---|---|---|---|---|---|---|---|
| MIAPaca2 | HeLa | A375 | MCF7 | HepG2 | SH-SY5Y | Jurkat | BJ | |
| 1 | 101.6 ± 1.6 | 107.2 ± 2.5 | 112.2 ± 2.6 | 97.8 ± 3.9 | 125.1 ± 9.1 | 109.7 ± 2.5 | 105.8 ± 5.0 | 165.0 ± 7.1 |
| 9 | 14.2 ± 0.9 | 12.4 ± 1.2 | 10.4 ± 1.0 | 6.4 ± 0.3 | 14.3 ± 0.3 | 6.0 ± 0.2 | 3.2 ± 0.1 | N.D. |
| 10 | 3.3 ± 0.2 | 2.2 ± 0.1 | 2.0 ± 0.2 | 3.0 ± 0.2 | 3.1 ± 0.1 | 1.7 ± 0.15 | 1.1 ± 0.06 | 6.9 ± 0.07 |
| 11 | 10.8 ± 0.2 | 10.9 ± 1.0 | 7.1 ± 0.3 | 5.6 ± 0.3 | 13.5 ± 0.4 | 5.6 ± 0.2 | 2.4 ± 0.1 | N.D. |
| 12 | 3.3 ± 0.2 | 2.6 ± 0.2 | 2.3 ± 0.2 | 3.2 ± 0.3 | 3.5 ± 0.2 | 2.2 ± 0.2 | 1.3 ± 0.12 | N.D. |
| 13 | 28.7 ± 2.6 | 28.9 ± 1.7 | 26.5 ± 0.9 | N.D. | N.D. | N.D. | N.D. | N.D. |
| 14 | 13.4 ± 0.5 | 11.8 ± 0.7 | 10.3 ± 1.0 | N.D. | N.D. | N.D. | N.D. | N.D. |
| 17 | 17.8 ± 1.1 | 22.2 ± 0.8 | 17.9 ± 0.2 | N.D. | N.D. | N.D. | N.D. | N.D. |
| 18 | 15.2 ± 0.5 | 17.9 ± 0.6 | 13.4 ± 1.0 | N.D. | N.D. | N.D. | N.D. | N.D. |
| 21 | 12.0 ± 1.0 | 10.6 ± 0.1 | 7.2 ± 0.5 | 6.0 ± 0.3 | 11.8 ± 0.4 | 3.7 ± 0.1 | 1.7 ± 0.10 | N.D. |
| 22 | 6.9 ± 0.3 | 5.4 ± 0.3 | 4.9 ± 0.1 | 5.2 ± 0.2 | 9.0 ± 0.1 | 3.2 ± 0.1 | 1.5 ± 0.12 | N.D. |
| Cisplatin | 5.0 ± 1.0 [46] | 2.3 ± 0.3 [43] | 3.1 ± 1.0 [42] | 19.1 ± 4.5 [43] | 2.9 [41] | 0.7 ± 0.1 [44] | 1.9 [45] | 10.1 ± 2.0 [43] |
1 The cell lines were treated with different concentrations of each compound for 72 h. IC50 values were determined by XTT assay in Jurkat and SH-SY5Y cells and by MTT assay in all the other cell lines. Results are expressed as means ± SD of three independent experiments. IC50 is the concentration that inhibits 50% of cellular growth. N.D.: not determined.